February 27th 2024
Shared insight on the future of diffuse large B-cell lymphoma management, highlighting unmet needs and hope for continued growth in the treatment landscape.
February 20th 2024
Jason Westin, MD, and expert panelists highlight additional clinical data presented at the 2023 American Society of Hematology annual meeting.
With the emergence of newer agents, panelists discuss their approaches to best sequence treatments for patients with R/R DLBCL.
February 13th 2024
A comprehensive overview of safety considerations for bispecific antibodies in patients treated for R/R DLBCL.
Experts transition their discussion to highlight the emergence of bispecific antibodies as an additional treatment option for patients with R/R DLBCL.
February 6th 2024
Focusing their discussion on therapeutic options for patients with R/R DLBCL, in the third line and beyond setting.
Clinical Oncologists focus their discussion on navigating toxicities specific to CAR T, highlighting cytokine release syndrome (CRS) and neurotoxicities.
January 30th 2024
Experts share clinical perspectives on the use of CAR T for patients with DLBCL, in the R/R setting.
Focused discussion on the latest updates of CAR Ts such as axi-cel and liso-cel from the ZUMA-7 and TRANSFORM trials, respectively.
January 29th 2024
Centering discussion on the role of CAR T-cell therapy for patients with R/R DLBCL.
Panelists consider real-world outcomes for treating patients with tafasitamab-lenalidomide for R/R DLBCL.
January 16th 2024
A comprehensive overview of tafasitamab plus lenalidomide for patients with relapsed/refractory DLBCL, highlighting data updates and the impact on clinical practice.
Expert perspectives on treatment selection for patients with R/R DLBCL receiving second line therapy.
A brief discussion on evolving practice standards and clinical perspectives that help to inform selection of best therapy for patients with DLBCL that progress beyond initial therapy.
December 19th 2023
Key opinion leaders on diffuse large B-cell lymphoma management provide a review first-line treatment options.
August 14th 2023
Krish Patel, MD, discusses the latest advances in the treatment of non-Hodgkin’s lymphoma and how fixed-duration treatment options can improve the overall patient experience.
September 29th 2022
Krish Patel, MD, discusses the factors to consider when treating patients with relapsed and/or refractory follicular lymphoma.
March 20th 2019
Krish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses emerging therapeutic strategies and ongoing research in mantle cell lymphoma (MCL).
March 11th 2019
Krish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses zanubrutinib in the treatment of patients with mantle cell lymphoma.
February 19th 2019
Krish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses induction therapy in patients with mantle cell lymphoma (MCL).